Ipca Laboratories (IPCALAB) Resumen de Acciones
Ipca Laboratories Limited, empresa farmacéutica, fabrica y comercializa formulaciones e ingredientes farmacéuticos activos (API) para diversos segmentos terapéuticos en India, Europa, África, América, Asia, CEI y Australasia. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 5/6 |
| Salud financiera | 5/6 |
| Dividendos | 3/6 |
IPCALAB Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Ipca Laboratories Limited
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | ₹1,970.90 |
| Máximo en las últimas 52 semanas | ₹2,001.50 |
| Mínimo de 52 semanas | ₹1,251.60 |
| Beta | 0.055 |
| Cambio en 1 mes | 12.73% |
| Variación en 3 meses | 24.50% |
| Cambio de 1 año | 50.20% |
| Variación en 3 años | 118.65% |
| Variación en 5 años | 53.31% |
| Variación desde la OPV | 5,086.58% |
Noticias y actualizaciones recientes
Actualización de narrativa • Sep 03
IPCALAB: Upcoming Amalgamation And Margin Outlook Will Shape Balanced Return Prospects
Analysts have lifted their price target for Ipca Laboratories from ₹1,719.61 to ₹1,972.28, citing adjusted assumptions on discount rate, profit margin and future P/E as key drivers of the change. What’s in the News for Ipca Laboratories A board meeting is scheduled on Jun 26, 2026, at 11:30 Indian Standard Time to consider approval of a Scheme of Amalgamation of Krebs Biochemicals & Industries Ltd.
Actualización de narrativa • Aug 15
IPCALAB: Amalgamation Meeting Will Drive Future Upside Potential
Analysts have raised their price target for Ipca Laboratories from ₹1,968 to ₹2,050, citing updated assumptions that reflect a slightly lower discount rate, a modestly adjusted revenue growth outlook, a higher profit margin, and a marginally lower future P/E multiple. What's in the News Ipca Laboratories has scheduled a board meeting on Jun 26, 2026 to consider approval of a Scheme of Amalgamation of Krebs Biochemicals & Industries Ltd.Recent updates
Actualización de narrativa • Sep 03
IPCALAB: Upcoming Amalgamation And Margin Outlook Will Shape Balanced Return Prospects
Analysts have lifted their price target for Ipca Laboratories from ₹1,719.61 to ₹1,972.28, citing adjusted assumptions on discount rate, profit margin and future P/E as key drivers of the change. What’s in the News for Ipca Laboratories A board meeting is scheduled on Jun 26, 2026, at 11:30 Indian Standard Time to consider approval of a Scheme of Amalgamation of Krebs Biochemicals & Industries Ltd.Actualización de narrativa • Aug 15
IPCALAB: Amalgamation Meeting Will Drive Future Upside Potential
Analysts have raised their price target for Ipca Laboratories from ₹1,968 to ₹2,050, citing updated assumptions that reflect a slightly lower discount rate, a modestly adjusted revenue growth outlook, a higher profit margin, and a marginally lower future P/E multiple. What's in the News Ipca Laboratories has scheduled a board meeting on Jun 26, 2026 to consider approval of a Scheme of Amalgamation of Krebs Biochemicals & Industries Ltd.Actualización de narrativa • Jul 17
IPCALAB: Board Reviews And Merger Plan Will Shape Measured Upside Potential
The analyst price target for Ipca Laboratories has shifted from ₹1,887 to about ₹1,968, with analysts linking this change to updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News Ipca Laboratories has scheduled a board meeting on May 29, 2026 to consider standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026, and to consider a dividend recommendation for the 2025-26 financial year.
Actualización de narrativa • Jul 03
IPCALAB: Lower Margin Outlook Will Pressure Upcoming Results And Dividend Decision
Analysts have adjusted their price target for Ipca Laboratories to ₹1,517.62 from ₹1,415.37, reflecting updated assumptions for slightly lower revenue growth, a reduced profit margin, and a lower future P/E multiple. What’s in the News for Ipca Laboratories Board meeting scheduled for May 29, 2026 to consider standalone and consolidated audited financial results for the fourth quarter and full financial year ended March 31, 2026.Actualización de narrativa • Jun 19
IPCALAB: Upcoming Board Results And Dividend Move Will Reinforce Bullish View
Analysts have lifted their price target for Ipca Laboratories stock to ₹1,720 from ₹1,655, reflecting updated assumptions that combine slightly different views on revenue growth, profit margins and future P/E levels. What’s in the News for Ipca Laboratories A board meeting of Ipca Laboratories is scheduled for May 29, 2026, to review standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026.Actualización de narrativa • Jun 04
IPCALAB: Higher Fair Value And Board Review Will Support Future Upside Potential
Analysts now set a higher fair value price target for Ipca Laboratories at ₹1,887, compared with ₹1,731 earlier, reflecting updated assumptions on revenue growth, profit margins and future P/E levels. What's in the News A board meeting is scheduled for May 29, 2026, to review standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026.Artículo de análisis • Jun 03
Should You Be Adding Ipca Laboratories (NSE:IPCALAB) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Actualización de narrativa • May 06
IPCALAB: Upcoming Results And Dividend Decision Will Shape Earnings Visibility
Analysts have nudged their fair value estimate for Ipca Laboratories slightly higher from ₹1,406.78 to ₹1,415.37, reflecting updated assumptions around revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled for May 29, 2026 to review standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026 (company filing).Actualización de narrativa • Apr 19
IPCALAB: Upcoming Results And Revised Assumptions Will Guide Earnings Visibility
Analysts have trimmed their fair value estimate for Ipca Laboratories slightly from about ₹1,416 to around ₹1,407, reflecting updated assumptions on future revenue growth, profit margins and a modestly lower future P/E multiple. What's in the News Board meeting scheduled on February 13, 2026, to consider and take on record the standalone unaudited financial results for the third quarter and nine months ended December 31, 2025 (company filing).Actualización de narrativa • Apr 05
IPCALAB: Upcoming Unaudited Results Will Support Bullish View On Steady Fair Value
Analysts have kept their fair value estimate for Ipca Laboratories steady at ₹1,655, reflecting unchanged assumptions around discount rate, revenue growth, profit margin and future P/E expectations. What's in the News A board meeting is scheduled for February 13, 2026 to consider and record the standalone unaudited financial results for the third quarter ended December 31, 2025 (Key Developments).Actualización de narrativa • Mar 22
IPCALAB: Upcoming Results Review And Margins Outlook Will Support Steady Fair Value
Analysts now set their fair value estimate for Ipca Laboratories at about ₹1,655, up from roughly ₹1,634. This reflects updated assumptions that include a slightly higher profit margin and P/E multiple, along with modest adjustments to projected revenue growth and an unchanged discount rate.Actualización de narrativa • Mar 07
IPCALAB: Upcoming Results And Revised Assumptions Will Shape Future Earnings Visibility
Analysts have raised their fair value estimate for Ipca Laboratories from ₹1,106 to about ₹1,416, reflecting updated assumptions on discount rates, revenue growth, profit margins and future P/E that they consider to more accurately capture the company’s earnings potential. What's in the News A board meeting is scheduled for February 13, 2026, to review and take on record the standalone and consolidated unaudited financial results for the third quarter and nine months ended December 31, 2025 (Key Developments).Actualización de narrativa • Feb 20
IPCALAB: Upcoming Board Results Review Will Support Upbeat Long Term Outlook
Analysts have nudged their fair value estimate for Ipca Laboratories up from about ₹1,565 to roughly ₹1,634, reflecting updated assumptions around revenue growth, profit margins and a higher future P/E multiple. What's in the News Board meeting scheduled for February 13, 2026, to review and take on record the standalone unaudited financial results for the third quarter and nine months ended December 31, 2025.Artículo de análisis • Feb 18
Here's What Analysts Are Forecasting For Ipca Laboratories Limited (NSE:IPCALAB) After Its Third-Quarter Results
It's been a good week for Ipca Laboratories Limited ( NSE:IPCALAB ) shareholders, because the company has just released...Artículo de análisis • Feb 12
Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Actualización de narrativa • Feb 06
IPCALAB: Upcoming Results Review Will Support Measured Outlook And Modest Assumption Shifts
Analysts have nudged their price target for Ipca Laboratories slightly higher, citing modest tweaks to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News A board meeting is scheduled for February 13, 2026, to consider and record standalone unaudited financial results for the third quarter ended December 31, 2025.Actualización de narrativa • Jan 23
IPCALAB: Firmer Margins And Tighter P E Will Support Future Upside Potential
Analysts have inched up their fair value estimate for Ipca Laboratories to ₹1,731 per share from ₹1,730 per share, citing updated assumptions around revenue growth, profit margins and a slightly lower future P/E multiple in their models. What's in the News Board meeting scheduled for February 13, 2026, to consider and record standalone and consolidated unaudited financial results for the third quarter and nine months ended December 31, 2025 (company filing).Artículo de análisis • Jan 21
Ipca Laboratories Limited's (NSE:IPCALAB) Earnings Haven't Escaped The Attention Of Investors
With a price-to-earnings (or "P/E") ratio of 45.1x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...Actualización de narrativa • Jan 08
IPCALAB: Board Meeting Schedule And Stable Assumptions Will Shape Balanced Outlook
Analysts have slightly raised their price target on Ipca Laboratories to ₹1,555 from ₹1,552, citing small adjustments to long term assumptions on revenue growth, profit margin and future P/E multiples. What's in the News Board meeting scheduled on Oct 17, 2025, at 17:00 Indian Standard Time (company filing) Board meeting set for Nov 13, 2025, to consider and record Standalone and Consolidated Unaudited Financial Results for the 2nd quarter and half year ended Sep 30, 2025 (company filing) Valuation Changes Fair Value: The analyst fair value estimate has moved marginally higher from ₹1,551.82 to ₹1,555.06 per share.Actualización de narrativa • Dec 24
IPCALAB: Improved Margins And Lower Multiple Will Support Future Upside Potential
Analysts have trimmed their price target on Ipca Laboratories by approximately ₹80 to around ₹1,730, reflecting slightly softer revenue growth assumptions, while still factoring in improved profit margins and a lower future P/E multiple. What's in the News Board meeting scheduled on October 17, 2025, at 17:00 IST to discuss corporate matters and ongoing strategic priorities (company filing).Actualización de narrativa • Dec 10
IPCALAB: Biosimilar Partnership And Board Meetings Will Shape Balanced Outlook
Analysts have nudged their price target for Ipca Laboratories slightly higher to approximately ₹1,552 from about ₹1,543, reflecting modestly improved valuation multiples, even though there were only minor trims to long term revenue growth and profit margin assumptions. What's in the News Ipca Laboratories and BioSimilar Sciences PR LLC entered a Technology Transfer and Joint Development Agreement to shift late stage development, clinical manufacturing, and commercial supply of a next generation anti cancer or anti inflammatory monoclonal antibody biosimilar to BSS sterile campus in Aguadilla, Puerto Rico (company announcement) A board meeting is scheduled on October 17, 2025, at 17:00 Indian Standard Time to review corporate matters (company filing) A board meeting is set for November 13, 2025, to consider and take on record the standalone and consolidated unaudited financial results for the second quarter and half year ended September 30, 2025 (company filing) Valuation Changes Fair Value Estimate has risen slightly from around ₹1,543 to about ₹1,552, reflecting a modestly higher intrinsic value.Artículo de análisis • Dec 09
Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Actualización de narrativa • Nov 26
IPCALAB: Technology Partnership and Upcoming Board Meetings Will Influence Outlook
Narrative Update on Ipca Laboratories Analysts have raised their price target for Ipca Laboratories from ₹1,529.94 to ₹1,542.56. This change reflects optimism due to improved forecasts for revenue growth and profit margins.Actualización de narrativa • Nov 11
IPCALAB: Technology Agreement With BioSimilar Sciences Will Drive Future Expansion
Analysts have raised their price target for Ipca Laboratories from ₹1,501.41 to ₹1,529.94, citing updated model assumptions and slight adjustments to long-term growth and margin forecasts. What's in the News Ipca Laboratories held a Board Meeting on October 17, 2025, at 17:00 Indian Standard Time.Artículo de análisis • Oct 19
Shareholders Should Be Pleased With Ipca Laboratories Limited's (NSE:IPCALAB) Price
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 27x, you may consider Ipca...
Nueva narrativa • Dec 12
Synergies With Unichem Laboratories And US Market Re-entry Will Boost Future Earnings
Strong domestic formulation growth and market share improvement position Ipca Laboratories for increased revenues and earnings.Rentabilidad de los accionistas
| IPCALAB | IN Pharmaceuticals | Mercado IN | |
|---|---|---|---|
| 7D | 0.8% | -0.4% | -0.6% |
| 1Y | 50.2% | 15.5% | -0.1% |
Rentabilidad vs. Industria: IPCALAB superó a la industria Indian Pharmaceuticals, que obtuvo un rendimiento del 15.5% el año pasado.
Rentabilidad vs. Mercado: IPCALAB superó al mercado Indian, que obtuvo un rendimiento del -0.1% el año pasado.
Volatilidad de los precios
| IPCALAB volatility | |
|---|---|
| IPCALAB Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in IN Market | 8.9% |
| 10% least volatile stocks in IN Market | 3.4% |
Precio estable de las acciones: IPCALAB no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado Indian.
Volatilidad a lo largo del tiempo: La volatilidad semanal de IPCALAB (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1949 | 17,210 | Pranay Godha | www.ipca.com |
Ipca Laboratories Limited, empresa farmacéutica, fabrica y comercializa formulaciones e ingredientes farmacéuticos activos (API) para diversos segmentos terapéuticos en India, Europa, África, América, Asia, CEI y Australasia. Ofrece API en las áreas terapéuticas de antihipertensivos, antipalúdicos, diuréticos, DMARD y antihelmínticos. La empresa también suministra formulaciones genéricas y de marca en los segmentos terapéuticos de alergia, antineoplásicos/cáncer, antiartríticos, antiepilépticos, antihipertensivos, cardiología, diabetes, dermatología, diabetología, emolientes/protectores, fiebre, gastroenterología, hematología, helmintos, hepatoprotectores, inmunosupresores, enfermedades infecciosas, paludismo, neurología, dolor neuropático y AINE, así como nutracéuticos, oftalmología, antidiabéticos orales, ortopedia, probióticos, psiquiatría, respiratorio, reumatología y urología.
Resumen de fundamentos de Ipca Laboratories Limited
| Estadísticas fundamentales de IPCALAB | |
|---|---|
| Capitalización bursátil | ₹498.17b |
| Beneficios(TTM) | ₹13.10b |
| Ingresos (TTM) | ₹101.26b |
38.2x
Ratio precio-beneficio (PE)4.9x
Ratio precio-ventas (PS)¿Está IPCALAB sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de IPCALAB | |
|---|---|
| Ingresos | ₹101.26b |
| Coste de los ingresos | ₹32.67b |
| Beneficio bruto | ₹68.59b |
| Otros gastos | ₹55.49b |
| Beneficios | ₹13.10b |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 51.63 |
| Margen bruto | 67.73% |
| Margen de beneficio neto | 12.93% |
| Ratio deuda/patrimonio | 8.5% |
¿Cómo se ha desempeñado IPCALAB a largo plazo?
Ver rendimiento histórico y comparativaDividendos
0.3%
Rentabilidad actual por dividendo13%
Ratio de pagos¿Paga IPCALAB dividendos fiables?
Ver historial de dividendos e índices de referencia de IPCALAB| fechas de dividendos de Ipca Laboratories | |
|---|---|
| Fecha ex dividendo | Aug 07 2026 |
| Fecha de pago de dividendos | Sep 10 2026 |
| Días hasta ex dividendo | 34 days |
| Días hasta la fecha de pago de dividendos | 0 days |
¿Paga IPCALAB dividendos fiables?
Ver historial de dividendos e índices de referencia de IPCALABAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/10 11:57 |
| Precio de las acciones al final del día | 2026/09/10 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Ipca Laboratories Limited está cubierta por 40 analistas. 17 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Aditya Khemka | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |